VONKO-027: Development and application of a therapy line algorithm, evaluation of data completeness and estimation of the number of patients in a SCLC population within the existing lung cancer cohort from the VONKO-001 project

VONKO-027: Development and application of a therapy line algorithm, evaluation of data completeness and estimation of the number of patients in a SCLC population within the existing lung cancer cohort from the VONKO-001 project - VONKOdb extensive stage SCLC 2025

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035925

Enrollment

6000

Registered

2025-01-24

Start date

2025-01-24

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Retrospective analysis of patients with SCLC diagnosed in 2016-2019

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: - diagnosis years 2016-2019 - place of residence in respective federal state of cancer registry - SCLC as histology (ICD-O-3: 8041-8045)

Exclusion criteria

Exclusion criteria: Patient is known to the cancer registry only by means of either - a death certificate - a pathology report - a follow up notification - a tumor conference report - a combination of the aforementioned

Design outcomes

Primary

Measure	Time frame
Evaluating the availability of key variables in pooled data from four cancer registries (Patient Data in the 70K lung cancer cohort) pertaining to an ES-SCLC cohort, emphasizing insights into data completeness, follow-up time available, and patient counts. The following granular objectives are considered: 1.Understand the patient counts achievable in Patient Data in the 70K lung cancer cohort by applying eligibility criteria in an attrition table format. 2.Describe the availability of data variables in Patient Data in the 70K lung cancer cohort. 3.Describe quantitatively the completeness of key data variables in Patient Data in the 70K lung cancer cohort. 4.Describe the longitudinality available in the patient cohort of Patient Data in the 70K lung cancer cohort.	—

Measure

Time frame

Evaluating the availability of key variables in pooled data from four cancer registries (Patient Data in the 70K lung cancer cohort) pertaining to an ES-SCLC cohort, emphasizing insights into data completeness, follow-up time available, and patient counts. The following granular objectives are considered: 1.Understand the patient counts achievable in Patient Data in the 70K lung cancer cohort by applying eligibility criteria in an attrition table format. 2.Describe the availability of data variables in Patient Data in the 70K lung cancer cohort. 3.Describe quantitatively the completeness of key data variables in Patient Data in the 70K lung cancer cohort. 4.Describe the longitudinality available in the patient cohort of Patient Data in the 70K lung cancer cohort.

—

Secondary

Measure	Time frame
Development of a robust and validated LoT algorithm to generate descriptive treatment outputs for an ES-SCLC cohort. The following granular objectives are considered: 1. Generate a descriptive set of rules to define lines of therapy (LoTs). 2. Apply the descriptive rules to the subgroup of ES-SCLC Patients in the 70K lung cancer cohort to produce patient count estimates based upon number of LoTs received. 3. Describe basic treatment characteristics of ES-SCLC patients (frequency of treatment types, duration per LoT, gaps between LoTs) in Patient Data in the 70K lung cancer cohort based upon application of the developed LoT algorithm.	—

Measure

Time frame

Development of a robust and validated LoT algorithm to generate descriptive treatment outputs for an ES-SCLC cohort. The following granular objectives are considered: 1. Generate a descriptive set of rules to define lines of therapy (LoTs). 2. Apply the descriptive rules to the subgroup of ES-SCLC Patients in the 70K lung cancer cohort to produce patient count estimates based upon number of LoTs received. 3. Describe basic treatment characteristics of ES-SCLC patients (frequency of treatment types, duration per LoT, gaps between LoTs) in Patient Data in the 70K lung cancer cohort based upon application of the developed LoT algorithm.

—

Countries

Germany

Contacts

Public ContactAnnika Waldmann

Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie

annika.waldmann@uksh.de+49 451 500 51240

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026